https://www.selleckchem.com/pr....oducts/nazartinib-eg
Short-bowel syndrome is the leading cause of pediatric intestinal failure, resulting in dependency on long-term parenteral nutrition (PN). To promote enteral autonomy in neonates, a key outcome may be intestinal growth in length. The purpose of this study was to determine if intestinal lengthening persists following discontinuation of treatment with 1 of 2 GLP-2 analogues with different pharmacokinetic profiles. Neonatal short-bowel piglets were assigned to saline control (S), 7-day treatment with teduglutide (T) (0.05
Like
Comment
Share
